The role of novel biomarkers in predicting diabetic nephropathy: a review

Samuel N Uwaezuoke
Pediatric Nephrology Firm, Department of Pediatrics, University of Nigeria Teaching Hospital, Ituku-Ozalla, Enugu, Nigeria

Abstract: Diabetic nephropathy (DN) is one of the microvascular complications of the kidney arising commonly from type 1 diabetes mellitus (T1DM), and occasionally from type 2 diabetes mellitus (T2DM). Microalbuminuria serves as an early indicator of DN risk and a predictor of its progression as well as cardiovascular disease risk in both T1DM and T2DM. Although microalbuminuria remains the gold standard for early detection of DN, it is not a sufficiently accurate predictor of DN risk due to some limitations. Thus, there is a paradigm shift to novel biomarkers which would help to predict DN risk early enough and possibly prevent the occurrence of end-stage kidney disease. These new biomarkers have been broadly classified into glomerular biomarkers, tubular biomarkers, biomarkers of inflammation, biomarkers of oxidative stress, and miscellaneous biomarkers which also include podocyte biomarkers, some of which are also considered as tubular and glomerular biomarkers. Although they are potentially useful for the evaluation of DN, current data still preclude the routine clinical use of majority of them. However, their validation using high-quality and large longitudinal studies is of paramount importance, as well as the subsequent development of a biomarker panel which can reliably predict and evaluate this renal microvascular disease. This paper aims to review the predictive role of these biomarkers in the evaluation of DN.

Keywords: type 1 diabetes mellitus, renal microvascular complication, microalbuminuria, end-stage kidney disease, biomarker panel

Introduction
Diabetic nephropathy (DN) is one of the renal microvascular complications which is commonly due to type 1 diabetes mellitus (T1DM), and occasionally due to type 2 diabetes mellitus (T2DM). It is a clinical syndrome comprising the following features: persistent albuminuria (or albuminuria excretion rate of >300 mg/d or 200 μg/min) recorded at least twice within a 3- to 6-month interval, progressive reduction in glomerular filtration rate (GFR), and hypertension. The evolution of DN occurs over a period of 10–20 years, beginning from microalbuminuria and progressing to end-stage kidney disease (ESKD). Thus, overt DN is very rare in the pediatric age group, although some previous reports have confirmed its occurrence in childhood. Notably, patients with DN and T1DM almost always present with other signs of diabetic microvascular disease such as retinopathy and neuropathy; in fact, retinopathy usually precedes the onset of overt DN in these patients.

Glomerular hyperfiltration occurs in the early stage of DN resulting in microalbuminuria. As the disease progresses, macroalbuminuria sets in and is followed by
deterioration in renal function and ESKD, which may eventually require renal replacement therapy. Microalbuminuria therefore serves not only as an indicator of DN risk but also as a strong predictor of its progression, and a predictor of cardiovascular disease risk in both T1DM and T2DM. For instance, 80% of T1DM patients with microalbuminuria will end up with overt nephropathy (macroalbuminuria) within 10–15 years, 50% of whom will develop ESKD within 10 years and 75% within 20 years if there are no appropriate therapeutic interventions. However, subsequent studies have disputed these previous observations. It is now projected that the rate of progression from microalbuminuria to macroalbuminuria over a 5- to 10-year period is about 15–30%, although as high as 45% in patients with less than 15 years of diabetes duration but much lower than the initially estimated figure of 80%.

Although microalbuminuria remains the gold standard marker for early detection of DN, it is not a sufficiently accurate predictor of DN risk given some limitations. For example, not all diabetics with microalbuminuria will end up with ESKD, and 30% of them may actually have normoalbuminuria, while several biomarkers of glomerular or tubular dysfunction can precede microalbuminuria, suggesting that microalbuminuria is present once significant renal injury has already occurred. Nevertheless, its predictive accuracy can be enhanced by other parameters such as a painstaking family history, consideration of absolute versus categorical urine albumin excretion (UAE) values, more frequent UAE estimates, ambulatory blood pressure monitoring, precise GFR measurements, diabetic retinopathy assessments, and plasma lipid profile. Interestingly, there is now a paradigm shift to novel biomarkers which would help to predict DN risk early enough, and possibly prevent the occurrence of ESKD. This paper aims to review the predictive role of these biomarkers in the evaluation of DN.

Pathogenesis of DN: overview of molecular mechanisms

Recent observations indicate that several pathways are activated during the development of diabetes mellitus; these pathways individually or collectively modulate the induction and progression of DN. Although the pathogenesis of DN is multifactorial, the mechanisms that propel its development remain largely unclear. During the course of DN, the functional derangement and structural remodeling of the kidney, triggered by hyperglycemic injury, are linked to changes in several cellular events and activation of signaling pathways.

These pathways interact in a cascade of complex molecular mechanisms, resulting in the major pathogenic components of DN, which consist of renal fibrosis, mesangial expansion, glomerular hypertrophy, oxidative stress, and tubular inflammation (Figure 1). Some biomarkers are linked to these pathways. For instance, the renin–angiotensin–aldosterone system is associated with inflammatory cytokines such as tumor necrosis factor α (TNF-α) and interleukin (IL) 1β, while substantial evidence suggests that angiotensin II and aldosterone are major mediators in the pathogenesis of DN. Furthermore, the role of protein kinase C (PKC) in the induction and progression of DN through a complex mechanism involving its isoforms (PKC-α, PKC-β, and PKC-ε) has been well reported. These isoforms have been implicated as mediators of renal fibrosis and mesangial expansion through upregulation of vascular endothelial growth factor (VEGF) expression in

![Figure 1](https://www.dovepress.com/)

Figure 1 A schematic representation of the pathogenesis of diabetic nephropathy.
mesangial cells, as well as transforming growth factor-\(\beta\) (TGF-\(\beta\)), type IV collagen, laminin, and fibronectin in the glomeruli. Even as hyperglycemia-induced expression of some NADPH oxidase subunits in mesangial cells occurs in a PKC-dependent fashion,\(^{34,35}\) NADPH oxidase-driven renal oxidative stress stimulates mesangial expansion and albuminuria by increasing the expression of fibronectin and collagen-1 in the kidney, TGF-\(\beta\)-1 being the main “fibrogenic” cytokine in vivo.\(^{36,37}\)

Finally, inflammatory cytokines such as TNF-\(\alpha\), IL-1, IL-6, and IL-18 are all involved in the development and progression to ESKD,\(^{39}\) while urinary TNF-\(\alpha\) excretion has been associated with severity of glomerular and tubulointerstitial injury in patients with T2DM.\(^{40}\)

**Albuminuria as the conventional biomarker**

Ideally, a little quantity of albumin is filtered in the glomerulus, and is accompanied by its near-complete reabsorption in the tubules.\(^{41}\) Thus, increased UAE is accepted as a well-established biomarker of glomerulopathy,\(^{16}\) as well as tubulopathy because in the latter, there is reduced reabsorption of the filtered albumin.\(^{42}\)

Since albuminuria is an important component of DN, it is important to establish the definition of the different degrees of UAE. Normoalbuminuria refers to UAE of <30 mg/day or 20 \(\mu\)g/min, while microalbuminuria and macroalbuminuria refer to UAE of 30–300 mg/day or 20–200 \(\mu\)g/min, and >300 mg/day or 200 \(\mu\)g/min, respectively.\(^{43}\)

Because baseline albuminuria is the strongest predictor of ESKD and cardiovascular morbidity in T2DM,\(^{44,45}\) the American Diabetes Association has recommended screening with yearly UAE in all patients with T2DM, commencing at the time of diagnosis.\(^{46}\)

Remarkably, microalbuminuria constitutes a risk factor for chronic kidney disease and ESKD, and also serves as a powerful predictor of cardiovascular morbidity and mortality in diabetic subjects.\(^{47–49}\) Nevertheless, about 30% of diabetics with renal dysfunction have normoalbuminuria,\(^{15}\) while the cardiovascular and renal morbidity is increased in the “high normal” range of UAE.\(^{49–52}\)

With these observations and the previously mentioned drawbacks, the use of albuminuria as the conventional biomarker for early detection of DN is thus becoming untenable. Moreover, recent evidence indicates that a remarkable number of patients with macroalbuminuria can revert to normoalbuminuria, while the concept of non-albuminuric DN is well documented, reflecting the fact that patients with diabetes mellitus can present with a reduction in GFR without progressing from normo- to macroalbuminuria.\(^{53}\) As a result, other biomarkers (reflective of glomerular or tubular injury) are now considered as more reliable, alternative predictors of DN risk. Since tubular lesions occur early in DN, markers of tubular injury will particularly be more useful than albuminuria in the early prediction of disease.

Recently, haptoglobin has been identified as another alternative dependable biomarker. By including the haptoglobin/creatinine ratio to a model using the albumin/creatinine ratio to predict early decline in renal function, some investigators reported an improvement in its predictive performance.\(^{54}\) Thus, it was concluded that the haptoglobin/creatinine ratio may be useful to predict patients with T2DM at risk of nephropathy prior to the onset of macroalbuminuria or reduced GFR.

**Novel biomarkers in DN**

Biomarkers of glomerular injury, tubular injury, inflammation, and oxidative stress precede albuminuria in some patients and thus may be useful for the early prediction of DN, although most of them still require validation.\(^{55,56}\) Because of the diversity of these novel biomarkers, different methods of classification have been documented for clarity.\(^{56}\)

Some authors have classified the biomarkers according to both their origin and the already-identified pathologic processes impairing the nephron such as kidney injury, oxidative stress, and inflammation: biomarkers of renal dysfunction, inflammatory biomarkers (cytokines and chemokines), and oxidative stress biomarkers.\(^{16}\) Others had proposed a classification which grouped the biomarkers into three categories: glomerular, tubular, and other proteins.\(^{57}\)

For the purpose of this review, a combination of these classifications will be used to discuss these markers (Table 1). It is equally important to note that an overlap exists in the categorization; some biomarkers of inflammation can also be regarded as glomerular markers, while some others that are grouped as miscellaneous biomarkers can also be seen as tubular or glomerular markers.

**Glomerular biomarkers**

These biomarkers include transferrin, immunoglobulin G (IgG), ceruloplasmin, type IV collagen, laminin, glycosaminoglycans (GAGs), lipocalin-type prostaglandin D synthase (L-PGDS), fibronectin, podocytes-podocalyxin, and VEGF.\(^{46}\)
Podocalyxin and VEGF are essentially considered as podocyte biomarkers.

Interestingly, newer approaches which can be used to identify potential novel biomarkers of DN have also been described; these include urinary microRNAs which are short noncoding mRNAs that regulate gene expression and urine proteomics, highlighting a possible role for epigenetic factors in the development of the disease. For instance, in a review to assess the correlation between changes in various mRNAs and progression of DN, some authors noted that mRNA-377, mRNA-192, mRNA-216/217, and mRNA-144 were elevated in body fluids of patients with DN, while mRNA-21 and mRNA-375 were decreased. They therefore suggested the plausibility of using urine-specific mRNAs as novel biomarkers for the diagnosis of early stages of DN. For glomerular biomarkers, urinary transferrin has been demonstrated as a more reliable marker of glomerular injury than albuminuria (Table 2). As a major serum iron-binding protein, transferrin conveys iron in its ferric forms to proliferative cells. Some reports indicate that prior to the development of microalbuminuria, urinary transferrin excretion appeared higher in diabetic subjects than in their healthy controls. In fact, urinary transferrin has been considered as a more sensitive biomarker of glomerular injury in diabetes mellitus. This is because patients with diabetes mellitus have increased likelihood of presenting with urinary transferrinuria than with albuminuria, while albumin/transferrin ratio is significantly lower in diabetic patients with normoalbuminuria and microalbuminuria than in those with macroalbuminuria. In addition, transferrinuria predicts the development of microalbuminuria in patients with T2DM who have normoalbuminuria. Moreover, in macroalbuminuric diabetic patients, urinary transferrin excretion is positively correlated with UAE. However, transferrinuria also occurs in primary glomerulonephritis, as well as systemic diseases which secondarily affect the glomerulus, thus underscoring its lack of specificity to DN.

Urinary IgG is another related biomarker. The immunoglobulin is an anionic plasma protein which crosses the glomerulus with difficulty, but appears in the urine concomitantly with elevated values of urinary transferrin, urinary ceruloplasmin, and urinary orosomucoid before the onset of

### Table 1 Classification of the novel biomarkers for diabetic nephropathy

<table>
<thead>
<tr>
<th>Biomarker</th>
<th>Tubular biomarkers</th>
<th>Glomerular biomarkers</th>
<th>Biomarkers of oxidative stress</th>
<th>Biomarkers of inflammation</th>
<th>Miscellaneous biomarkers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Transferrin</td>
<td>NGAL</td>
<td></td>
<td>8oHdG</td>
<td>TNF-α</td>
<td>VEGF</td>
</tr>
<tr>
<td>Albumin</td>
<td>KIM-I</td>
<td></td>
<td></td>
<td>IL-1β</td>
<td>Podocalyxin</td>
</tr>
<tr>
<td>IgG</td>
<td>NAG</td>
<td></td>
<td></td>
<td>IL-8</td>
<td>Neprhin</td>
</tr>
<tr>
<td>Ceruloplasmin</td>
<td>Cystatin C</td>
<td></td>
<td></td>
<td>IL-18</td>
<td>H-FABP</td>
</tr>
<tr>
<td>Type IV collagen</td>
<td>L-FABP</td>
<td></td>
<td></td>
<td>IP-10</td>
<td>Retinol-binding protein</td>
</tr>
<tr>
<td>Laminin</td>
<td>α-1-microglobulin</td>
<td></td>
<td></td>
<td>MCP-1</td>
<td>AGES</td>
</tr>
<tr>
<td>GAGs</td>
<td></td>
<td></td>
<td></td>
<td>G-CSF</td>
<td></td>
</tr>
<tr>
<td>Fibronectin</td>
<td></td>
<td></td>
<td></td>
<td>Eotaxin</td>
<td></td>
</tr>
<tr>
<td>L-PGDS</td>
<td></td>
<td></td>
<td></td>
<td>Orosomucoid</td>
<td></td>
</tr>
</tbody>
</table>

Notes: ‡ Also regarded as glomerular biomarkers. * Also regarded as tubular biomarkers.

Abbreviations: IgG, immunoglobulin G; GAGs, glycosaminoglycans; L-PGDS, lipocalin-type prostaglandin D synthase; NGAL, neutrophil gelatinase-associated lipocalin; KIM-I, kidney injury molecule 1; NAG, N-acetylgalactosaminidase; L-FABP, liver-type fatty acid-binding protein; 8oHdG, 8-oxo-7,8-dihydro-2-deoxyguanosine; TNF-α, tumor necrosis factor α; IL, interleukin; IP-10, interferon gamma-induced protein; MCP-1, monocyte chemotactic protein 1; G-CSF, granulocyte colony-stimulating factor; RANTES, regulated on activation, normal T cell expressed and secreted; VEGF, vascular endothelial growth factor; H-FABP, heart fatty acid-binding protein; AGES, advanced glycation end products.

### Table 2 Summary of some of the novel biomarkers for diabetic nephropathy

<table>
<thead>
<tr>
<th>Biomarker</th>
<th>Type of renal injury</th>
<th>T1DM</th>
<th>T2DM</th>
<th>Pre-microalbuminuria</th>
<th>Predicts microalbuminuria</th>
</tr>
</thead>
<tbody>
<tr>
<td>Urinary transferrin</td>
<td>Glomerular injury</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Urinary TNF-α</td>
<td>Glomerular injury</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Urinary type IV collagen</td>
<td>Glomerular/tubular injury</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Urinary fibronectin</td>
<td>Glomerular injury</td>
<td>+</td>
<td>+</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Urinary GAGs</td>
<td>Glomerular injury</td>
<td>+</td>
<td>+</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Urinary NAG</td>
<td>Tubular injury</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Urinary L-PGDS</td>
<td>Glomerular injury</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
</tbody>
</table>

Note: ‡ Appears in urine before microalbuminuria.

Abbreviations: T1DM, type 1 diabetes mellitus; T2DM, type 2 diabetes mellitus; TNF-α, tumor necrosis factor α; GAGs, glycosaminoglycans; NAG, N-acetylgalactosaminidase; L-PGDS, lipocalin-type prostaglandin D synthase.
microalbuminuria, which suggests the ability of increased elimination of urinary IgG to predict microalbuminuria in DM patients.\textsuperscript{73} For urinary ceruloplasmin, this copper-transporting serum protein is filtered with difficulty through the glomerular barrier because it is negatively charged like IgG.\textsuperscript{74} Similar to urinary transferrin and urinary IgG, urinary ceruloplasmin can predict DN earlier than albuminuria in T2DM patients; in fact, the values of the three markers can be elevated concomitantly.\textsuperscript{75} Both laminin and type IV collagen are components of glomerular basement membrane, although the latter is also a component of mesangial matrix. Since elevated urinary levels of type IV collagen occur in normoalbuminuric patients with T1DM, the biomarker can also be used as an early predictor of DN,\textsuperscript{75} and has actually been considered to be a specific indicator of early DN.\textsuperscript{76}

Moreover, some studies indicate that urinary excretion of type IV collagen in T2DM is related to UAE,\textsuperscript{77–79} while other investigators have shown that T2DM patients with evidence of kidney disease present with a significantly higher type IV collagen/albumin ratio compared to their nondiabetic counterparts with nephropathy.\textsuperscript{77,78} Again, these findings support the possible use of urinary type IV collagen in the differentiation of DN from nondiabetic nephropathy. Finally, urinary type IV collagen has also been found to show more sensitivity than albuminuria in the detection of renal injury in patients with T2DM,\textsuperscript{75} although other authors have reported that as many as one third of patients with microalbuminuria do not have increased urinary type IV collagen excretion.\textsuperscript{80} Remarkably, several studies have shown that urinary laminin excretion is higher in patients with diabetes mellitus in comparison to their healthy controls, even prior to the onset of microalbuminuria.\textsuperscript{78,81,82} To buttress the discriminatory role of this biomarker in diabetic and nondiabetic kidney disease, it has been reported that patients with T2DM who show evidence of nephropathy present with significantly higher laminin/albumin ratio compared to patients with nondiabetic nephropathy.\textsuperscript{78}

Urinary fibronectin is probably another useful biomarker of DN, but its relevance compared to albuminuria needs to be validated by further studies. Nevertheless, as an intrinsic component of the glomerular extracellular matrix, the urinary excretion of this high-molecular-weight protein is noted to be higher in subjects with diabetes mellitus compared to their controls, with a significant difference observed only in patients with macroalbuminuria.\textsuperscript{83,84} Further evidences pointing to its possible predictive role in DN include its higher excretion in diabetic subjects with microalbuminuria than in those with normoalbuminuria,\textsuperscript{83} the correlation of its urinary levels with the progression of biopsy-proven glomerular diffuse lesions,\textsuperscript{85} and the correlation of its degradation products with UAE.\textsuperscript{86}

Urinary GAGs are increased in DM patients with normoalbuminuria,\textsuperscript{87} and are associated with other tubular markers such as Tamm–Horsfall protein, which expresses a distal tubular dysfunction in patients with diabetes mellitus.\textsuperscript{88} GAGs are also present at the level of the tubular basement membrane. Finally, L-PGDS is a biomarker related to lesions of the glomerular capillary walls and reflects their increased permeability. Although it is basically considered to predict renal lesions, it is less relevant as an early biomarker of DN.\textsuperscript{89}

### Tubular biomarkers

Notably, tubulointerstitial lesions are also associated with glomerular injury during DN.\textsuperscript{90} Interestingly, tubular biomarkers have shown that tubular dysfunction can be present early in DN, occasionally preceding glomerular injury. This observation underscores the fact that tubular biomarkers are early predictors of DN compared to microalbuminuria and other glomerular biomarkers. Examples of tubular biomarkers include neutrophil gelatinase-associated lipocalin (NGAL), α-1-microglobulin, kidney injury molecule 1 (KIM-1), N-acetyl-β-D-glucosaminidase (NAG), cystatin C, and liver-type fatty acid-binding protein (L-FABP).

A recent review of diagnostic markers which can detect DN at an early stage shows that urinary tubular markers like NAG, α-1-microglobulin, L-FABP, as well as other makers such as nephrin and angiotensinogen may be elevated before the appearance of microalbuminuria in T2DM.\textsuperscript{91}

Similarly, elevated urinary NGAL is present in normoalbuminuric diabetic patients, as well as used to assess tubular lesions in the disease,\textsuperscript{92} and has been shown to precede microalbuminuria in T1DM.\textsuperscript{93,94} In addition, high values of this biomarker were noted in T2DM patients with normoalbuminuria which rose progressively in patients with microalbuminuria and macroalbuminuria.\textsuperscript{95} Thus, urinary NGAL in T2DM patients likely has a role in predicting the evolution of disease.\textsuperscript{96}

Regarding α-1-microglobulin, it is normally filtered through the glomerulus and reabsorbed in the proximal tubule; tubular dysfunction thus impairs its reabsorption resulting in its urinary excretion. A study has shown that normoalbuminuric T2DM patients had elevated urinary levels of this biomarker, given that tubular injury precedes the onset of microalbuminuria, making it a more sensitive and an earlier urinary biomarker.\textsuperscript{97} Besides, urinary α-1-microglobulin in early stages of diabetes mellitus could also have a role in
predicting DN, and has been identified as an inexpensive biomarker for the early diagnosis of DN.

There appears to be disparate findings about the sensitivity of NAG as a biomarker for the early prediction of DN. While some authors reported that NAG can be considered an early tubular biomarker as well as the most sensitive biomarker for detecting early renal injury in diabetic patients, others failed to demonstrate any clinical significance as an early biomarker of DN. Nevertheless, as a sensitive tubular biomarker, increased urinary NAG can precede the appearance of microalbuminuria in T1DM.

For cystatin C, its urinary excretion suggests tubular injury as it is elevated early in diabetes and prediabetic nephropathy, together with NGAL. Besides the predictive role of urinary cystatin C for the progression of DN, its serum and urinary levels are useful biomarkers for assessing early nephropathy in T2DM.

Although KIM-1, as tubular transmembrane glycoprotein, is a well-known sensitive biomarker for acute kidney injury, increased urinary levels have been reported in normoalbuminuric T2DM patients, indicating lesions of the proximal tubule in early stages of the disease. Moreover, microalbuminuric patients have higher urinary KIM-1 levels than those with normoalbuminuria. Another tubular biomarker with good predictive ability for diabetic kidney disease is urinary L-FABP. Elevated levels of this biomarker were found in normoalbuminuric T1DM patients; urinary L-FABP has a predictive role with respect to the evolution toward microalbuminuria, and of microalbuminuria toward macroalbuminuria. Similarly, patients with normoalbuminuric T2DM also presented high levels of urinary L-FABP, this protein being considered as a useful biomarker for diagnosing early DN as well as an independent predictor of the progression of DN.

**Biomarkers of inflammation**

Biomarkers of inflammation such as TNF-α and IL-1β, which are cytokines involved in the onset and progression of DN, also play predictive roles in the DN. A study by a group of researchers was the first to suggest that these proinflammatory cytokines could participate in the development of DN. In this study, macrophages incubated with glomerular basement membranes from diabetic rats produced significantly greater levels of IL-1β and TNF-α than macrophages incubated with membranes of normal nondiabetic rats. However, scientific attention has been directed more at the implications of TNF-α in the context of DN. TNF-α is reported to exert cytotoxic effect on glomerular, mesangial, and epithelial cells, and may trigger direct renal injury. In addition, increased urinary TNF-α excretion and elevated TNF-α levels in renal interstitial fluid have been observed to precede a significantly increased albuminuria in experimental murine models. Similarly, the findings from clinical studies indicate a direct and significant relationship between urinary protein excretion and serum TNF-α in diabetic patients with normal renal function and microalbuminuria on one hand, as well as in patients with overt nephropathy and ESKD on the other hand. Notably, the fact that urinary TNF-α levels are elevated in diabetic patients who have increased UAE, coupled with the significant rise of urinary TNF-α excretion as DN progresses, strongly supports the prospect of using this cytokine as a biomarker for predicting DN.

Other biomarkers of inflammation, which are also glomerular markers, include IL-18, interferon gamma-induced protein (IP-10), monocyte chemotactant protein 1 (MCP-1), granulocyte colony-stimulating factor (G-CSF), eotaxins, RANTES (regulated on activation, normal T cell expressed and secreted) or CCL-5, and orosomucoid. IL-18 is a proinflammatory cytokine originating from mononuclear cells. Its serum and urinary levels have been reported to correlate positively with albumin excretion rate, while its serum levels also correlate positively with carotid intima-media thickness in patients with T2DM, and thus may be a predictor of DN progression, as well as cardiovascular diseases. IP-10 and MCP-1 are other proinflammatory cytokines whose serum levels are significantly increased in subjects with T2DM. Moreover, serum and urinary levels of these two proinflammatory cytokines were found to be positively correlated with albumin excretion rate and intima-media thickness, suggesting that microinflammation may be a common risk factor for DN and atherosclerosis in T2DM. Serum and urinary G-CSF levels are also increased in the early stages of DN, while urinary RANTES (or CCL-5) and eotaxin excretion rates were noted to be significantly higher in hyperfiltration than in normofiltering T1DM patients. Like RANTES which is a chemotactic cytokine, eotaxins are a chemotactic cytokine subfamily of eosinophil chemotactic proteins consisting of eotaxin-1 (CCL-11), eotaxin-2 (CCL-24), and eotaxin-3 (CCL-26). The high urinary levels of eotaxin and RANTES, from hyperfiltration in the diabetic kidney, occur as result of high intraglomerular pressure which causes renal inflammation, inflammation being a component of DN.

Finally, some investigators reported high IL-8 and MCP-1 levels in early and late stages of DN in T2DM patients, respectively, while another study on T2DM patients with...
normoalbuminuria and microalbuminuria reported higher values of IL-8, IP10, MCP-1, G-CSF, eotaxin, and RANTES in patients with microalbuminuria than in those with normoalbuminuria. 126 Urinary orosomucoid has been noted to be high in T1DM patients with normoalbuminuria than in controls, while the levels increase in patients with microalbuminuria and macroalbuminuria. 127 In addition, T2DM patients were reported to present with increased urinary orosomucoid, in parallel with the excretion of IgG, ceruloplasm, and transferrin. 128

Biomarkers of oxidative stress
A typical example of a biomarker of oxidative stress is urinary 8-oxo-7,8-dihydro-2-deoxyguanosine (8OHdG). This marker is produced secondary to oxidative DNA damage, and appears in the urine without being metabolized. 129 Remarkably, urinary 8OHdG has been reported as a useful clinical marker to predict the development of DN in diabetic patients given the observation of a significant progression of DN in the patients with higher excretion of the biomarker in urine compared with their counterparts with moderate or lower excretion of the molecule. 130

Miscellaneous biomarkers
These include some tubular markers such as urinary heart fatty acid-binding protein and urinary retinol-binding protein, podocyte biomarkers such as podocalyxin, nephrin, and VEGF, as well as urinary proteomics and urinary advanced glycation end products (AGEs). These podocyte biomarkers are also regarded as glomerular markers. Nephrin is a slit diaphragm protein whose expression is reduced in late proteinuric phase of experimental DN, suggesting that reduced nephrin expression may be a determinant of glomerular hyperpermeability in DN. 131, 132 Since podocyte dysfunction occurs in diabetes mellitus and DN is actually considered a podocytopathy, nephrinuria has been reported in some T1DM patients before the onset of microalbuminuria, 133 as well as in some normoalbuminuric T2DM patients. 134 Furthermore, another podocyte biomarker like urinary VEGF has been found to be increased in T2DM patients with microalbuminuria and macroalbuminuria, 135 while higher levels of podocalyxin were seen in diabetic patients with microalbuminuria than in diabetic patients with normoalbuminuria. 136 Finally, some authors have reported that high values of urinary AGEs were seen in 50% of the T2DM patients with normoalbuminuria and in 85% of those with microalbuminuria. 137

Conclusion
Albuminuria is the conventional biomarker for the detection and prediction of DN and cardiovascular risk in T1DM and T2DM, although it has several limitations. Thus, there is now a focus on novel biomarkers which have higher sensitivity and specificity for earlier detection of DN, as well as for a more precise prediction of its progression to ESKD.

Although these biomarkers are potentially useful for the evaluation of diabetic kidney disease, current data still preclude the routine clinical use of majority of them. Nevertheless, the research trajectory on novel biomarkers for DN should take the course of persistent efforts at their discovery, their validation using high-quality and large longitudinal studies, and subsequent development of a biomarker panel which can reliably predict and evaluate this renal microvascular disease.

Acknowledgments
The author acknowledges the invaluable information obtained from the studies by Arora and Singh, 17 Cohen-Bucay and Viswanathan, 41 and Gluhovschi et al 56 during the preparation of the manuscript.

Disclosure
The author reports no conflicts of interest in this work.

References


52. Uwaezuoke | www.dovepress.com | For personal use only.

Dovepress


113. Navarro JF, Mora C, Maca M, Garca J. Inflammatory parameters are
111. Panduru NM, Forsblom C, Saraheimo M, et al; FinnDiane Study
107. Kim SS, Song SH, Kim IJ, et al. Urinary cystatin C and tubular pro-
106. Garg V, Kumar M, Mahapatra HS, Chitkara A, Gadpayle AK, Sekhar
105. Kim SS, Tawfeek S, Rasheld EA, El-Lebedy D, Thabet EH. Serum
92. Nakamura A, Shikata K, Nakatou T, Hiramatsu M, Makino H. Microinflammation is a common risk factor for progression of
89. Shore N, Khurshid R, Saleem M. Alpha-1microglobulin: a marker for
86. Wainai H, Katsukawa F, Takei I, Maruyama H, Kataoka K, Saruta T.
84. Wainai H, Katsukawa F, Takei I, Maruyama H, Kataoka K, Saruta T.
82. Wainai H, Katsukawa F, Takei I, Maruyama H, Kataoka K, Saruta T.
78. Wainai H, Katsukawa F, Takei I, Maruyama H, Kataoka K, Saruta T.
77. Wainai H, Katsukawa F, Takei I, Maruyama H, Kataoka K, Saruta T.
76. Wainai H, Katsukawa F, Takei I, Maruyama H, Kataoka K, Saruta T.
75. Wainai H, Katsukawa F, Takei I, Maruyama H, Kataoka K, Saruta T.
74. Wainai H, Katsukawa F, Takei I, Maruyama H, Kataoka K, Saruta T.
73. Wainai H, Katsukawa F, Takei I, Maruyama H, Kataoka K, Saruta T.
70. Wainai H, Katsukawa F, Takei I, Maruyama H, Kataoka K, Saruta T.
68. Wainai H, Katsukawa F, Takei I, Maruyama H, Kataoka K, Saruta T.
64. Wainai H, Katsukawa F, Takei I, Maruyama H, Kataoka K, Saruta T.
60. Wainai H, Katsukawa F, Takei I, Maruyama H, Kataoka K, Saruta T.
52. Wainai H, Katsukawa F, Takei I, Maruyama H, Kataoka K, Saruta T.
47. Wainai H, Katsukawa F, Takei I, Maruyama H, Kataoka K, Saruta T.
44. Wainai H, Katsukawa F, Takei I, Maruyama H, Kataoka K, Saruta T.
42. Wainai H, Katsukawa F, Takei I, Maruyama H, Kataoka K, Saruta T.
34. Wainai H, Katsukawa F, Takei I, Maruyama H, Kataoka K, Saruta T.